Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amplifine (also known as Amplifine PRP) is an autologous platelet-rich plasma (PRP) product used in regenerative medicine and aesthetic procedures. Originally developed by Suneva Medical and acquired by Tiger Aesthetics Medical (a division of Tiger BioSciences) in October 2024, the system is designed to concentrate platelets from a patient's own peripheral blood. Upon injection into target tissues, these concentrated platelets release a variety of growth factors—including PDGF, TGF-β, and VEGF—from their alpha granules. These factors stimulate cellular proliferation, angiogenesis, and collagen production, leading to tissue repair and skin rejuvenation. It is primarily utilized for aesthetic indications such as soft tissue augmentation and the treatment of fine lines and wrinkles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amplifine.